Friday Aug 15
Keryx Biopharmaceuticals Given Average Rating of "Buy" by Analysts
Shares of Keryx Biopharmaceuticals have been given a consensus recommendation of "Buy" by the twelve ratings firms that are presently covering the company, AnalystRatings.NET reports .
Thu Aug 14, 2014
Wed Aug 13, 2014
FBR Capital Markets Initiates Coverage on Keryx Biopharmaceuticals
The firm set a "market perform" rating on the stock. Keryx Biopharmaceuticals traded up 1.58% during mid-day trading on Wednesday, hitting $16.76.
Mon Aug 11, 2014
Keryx Biopharmaceuticals Given Consensus Recommendation of "Buy" by Analysts
Keryx Biopharmaceuticals has been given a consensus rating of "Buy" by the eleven ratings firms that are covering the stock, Analyst Ratings News reports .
Fri Aug 08, 2014
Keryx Biopharmaceuticals Given New $30.00 Price Target at Mizuho
Mizuho's target price would suggest a potential upside of 90.84% from the stock's previous close.
Thu Aug 07, 2014
Portfolio Report Card: A Retirement Portfolio Weighed Down By Cost
What is the optimal investment portfolio? Is it the one that contains the hottest performing stocks and funds? Actually, it's the portfolio that perfectly represents a person's psychology, life circumstances, financial needs, and future goals.
Keryx Biopharmaceuticals, Inc. Announces Second Quarter and Six Month 2014 Financial Results
"As we prepare to complete the transition to a commercial-stage company, we have added a wealth of talent to the organization, most recently with the hiring of our regional sales directors.
Tue Aug 05, 2014
Keryx Biopharmaceuticals To Host Conference Call On Second Quarter 2014 Financial Results
Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease, today announced that a conference call will be held on Thursday, August 7, 2014 at 8:00 a.m. EDT to discuss results for the second quarter of 2014 and provide an update on the business.
Wed Jul 30, 2014
Keryx Should Move Substantially In The Next Two Months
Keryx is a small biotech company with the license to a novel treatment for chronic kidney disease that the FDA is reviewing, with a goal date of September 7th.
Mon Jul 28, 2014
Medical News Today
Long-term Phase 3 study results for Zerenex (ferric citrate) published
Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Thu Jul 24, 2014
Ferric Citrate May Reduce Dialysis Patients' Need for Multiple Medications
A medication called ferric citrate may reduce dialysis patients' need to take multiple drugs that treat complications related to kidney disease.
Keryx Announces Zerenex LT Phase 3 Results Shows 'Highly ...
Keryx Biopharmaceuticals, Inc. announced the publication of results from the long-term, randomized, active control Phase 3 study of Zerenex , the Company's investigational oral ferric iron-based phosphate binder, for the treatment of hyperphosphatemia in patients with end-stage renal disease on dialysis.
Keryx drug improves phosphorus, iron in kidney patients -trial
A pivotal trial of Keryx Biopharmaceuticals Inc's experimental drug Zerenex showed that it improved levels of serum phosphorus and iron in patients on kidney dialysis, according to results published on Thursday.